Nature Clinical Practice Rheumatology Nature Clinical Practice Rheumatology provides physicians with authoritative and timely interpretations of key developments in the field, translating the latest findings into clinical practice. http://www.nature.com/ncprheum/current_issue/ Nature Publishing Group en © 2008 Nature Publishing Group Nature Clinical Practice Rheumatology 1745-8382 1745-8390 © 2008 Nature Publishing Group permissions@nature.com Nature Clinical Practice Rheumatology http://www.nature.com/includes/rj_globnavimages/ncprheum_logo.gif http://www.nature.com/ncprheum/ Genetics of osteoarthritis: early developmental clues to an old disease http://dx.doi.org/10.1038/ncprheum0935 Genetics of osteoarthritis: early developmental clues to an old disease

Nature Clinical Practice Rheumatology 4, 563 (2008). doi:10.1038/ncprheum0935

Authors: Eline Slagboom & Ingrid Meulenbelt

]]> Genetics of osteoarthritis: early developmental clues to an old disease Eline Slagboom Ingrid Meulenbelt doi:10.1038/ncprheum0935 Nature Clinical Practice Rheumatology 4, 563 (2008) Nature Clinical Practice Rheumatology 4 11 Editorial 563 563 Intensified COBRA therapy induces remission in 90% of patients with early RA http://dx.doi.org/10.1038/ncprheum0911 Intensified COBRA therapy induces remission in 90% of patients with early RA

Nature Clinical Practice Rheumatology 4, 564 (2008). doi:10.1038/ncprheum0911

]]> Intensified COBRA therapy induces remission in 90% of patients with early RA doi:10.1038/ncprheum0911 Nature Clinical Practice Rheumatology 4, 564 (2008) Nature Clinical Practice Rheumatology 4 11 Research Highlights 564 564 Power Doppler ultrasonography is useful to evaluate clinical response to therapy http://dx.doi.org/10.1038/ncprheum0912 Power Doppler ultrasonography is useful to evaluate clinical response to therapy

Nature Clinical Practice Rheumatology 4, 564 (2008). doi:10.1038/ncprheum0912

]]> Power Doppler ultrasonography is useful to evaluate clinical response to therapy doi:10.1038/ncprheum0912 Nature Clinical Practice Rheumatology 4, 564 (2008) Nature Clinical Practice Rheumatology 4 11 Research Highlights 564 564 Non-contrast-enhanced MRI can accurately assess synovitis in patients with knee OA http://dx.doi.org/10.1038/ncprheum0913 Non-contrast-enhanced MRI can accurately assess synovitis in patients with knee OA

Nature Clinical Practice Rheumatology 4, 564 (2008). doi:10.1038/ncprheum0913

]]> Non-contrast-enhanced MRI can accurately assess synovitis in patients with knee OA doi:10.1038/ncprheum0913 Nature Clinical Practice Rheumatology 4, 564 (2008) Nature Clinical Practice Rheumatology 4 11 Research Highlights 564 565 Algorithm that predicts progression of undifferentiated arthritis has been validated http://dx.doi.org/10.1038/ncprheum0914 Algorithm that predicts progression of undifferentiated arthritis has been validated

Nature Clinical Practice Rheumatology 4, 565 (2008). doi:10.1038/ncprheum0914

]]> Algorithm that predicts progression of undifferentiated arthritis has been validated doi:10.1038/ncprheum0914 Nature Clinical Practice Rheumatology 4, 565 (2008) Nature Clinical Practice Rheumatology 4 11 Research Highlights 565 565 Quantitative MRI provides insights into the efficacy of licofelone for knee OA http://dx.doi.org/10.1038/ncprheum0915 Quantitative MRI provides insights into the efficacy of licofelone for knee OA

Nature Clinical Practice Rheumatology 4, 565 (2008). doi:10.1038/ncprheum0915

]]> Quantitative MRI provides insights into the efficacy of licofelone for knee OA doi:10.1038/ncprheum0915 Nature Clinical Practice Rheumatology 4, 565 (2008) Nature Clinical Practice Rheumatology 4 11 Research Highlights 565 566 Revised MRI criteria needed for juvenile osteochondritis dissecans lesions http://dx.doi.org/10.1038/ncprheum0916 Revised MRI criteria needed for juvenile osteochondritis dissecans lesions

Nature Clinical Practice Rheumatology 4, 566 (2008). doi:10.1038/ncprheum0916

]]> Revised MRI criteria needed for juvenile osteochondritis dissecans lesions doi:10.1038/ncprheum0916 Nature Clinical Practice Rheumatology 4, 566 (2008) Nature Clinical Practice Rheumatology 4 11 Research Highlights 566 566 Bazedoxifene reduces the risk of fracture in women with postmenopausal osteoporosis http://dx.doi.org/10.1038/ncprheum0917 Bazedoxifene reduces the risk of fracture in women with postmenopausal osteoporosis

Nature Clinical Practice Rheumatology 4, 566 (2008). doi:10.1038/ncprheum0917

]]> Bazedoxifene reduces the risk of fracture in women with postmenopausal osteoporosis doi:10.1038/ncprheum0917 Nature Clinical Practice Rheumatology 4, 566 (2008) Nature Clinical Practice Rheumatology 4 11 Research Highlights 566 566 In briefs http://dx.doi.org/10.1038/ncprheum0918 In briefs

Nature Clinical Practice Rheumatology 4, 567 (2008). doi:10.1038/ncprheum0918

]]> In briefs doi:10.1038/ncprheum0918 Nature Clinical Practice Rheumatology 4, 567 (2008) Nature Clinical Practice Rheumatology 4 11 Research Highlights 567 567 Adverse effects of low-dose glucocorticoids and DMARD therapy in patients with RA—a complex relationship? http://dx.doi.org/10.1038/ncprheum0901 Adverse effects of low-dose glucocorticoids and DMARD therapy in patients with RA—a complex relationship?

Nature Clinical Practice Rheumatology 4, 568 (2008). doi:10.1038/ncprheum0901

Author: John Kirwan

]]> Adverse effects of low-dose glucocorticoids and DMARD therapy in patients with RA—a complex relationship? John Kirwan doi:10.1038/ncprheum0901 Nature Clinical Practice Rheumatology 4, 568 (2008) 2008-09-09 Nature Clinical Practice Rheumatology 2008-09-09 4 11 Practice Point 568 569 Bisphosphonate treatment for patients with chronic nonbacterial osteomyelitis http://dx.doi.org/10.1038/ncprheum0908 Bisphosphonate treatment for patients with chronic nonbacterial osteomyelitis

Nature Clinical Practice Rheumatology 4, 570 (2008). doi:10.1038/ncprheum0908

Authors: Henner Morbach, Martin Stenzel & Hermann J Girschick

]]> Bisphosphonate treatment for patients with chronic nonbacterial osteomyelitis Henner Morbach Martin Stenzel Hermann J Girschick doi:10.1038/ncprheum0908 Nature Clinical Practice Rheumatology 4, 570 (2008) 2008-09-16 Nature Clinical Practice Rheumatology 2008-09-16 4 11 Clinical Advance 570 571 Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis? http://dx.doi.org/10.1038/ncprheum0900 Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis?

Nature Clinical Practice Rheumatology 4, 572 (2008). doi:10.1038/ncprheum0900

Author: Cem Gabay

]]> Is tocilizumab a good therapeutic option for RA and systemic-onset juvenile idiopathic arthritis? Cem Gabay doi:10.1038/ncprheum0900 Nature Clinical Practice Rheumatology 4, 572 (2008) 2008-09-09 Nature Clinical Practice Rheumatology 2008-09-09 4 11 Clinical Advance 572 573 Is rituximab suitable for use as a first-line biologic therapy for RA? http://dx.doi.org/10.1038/ncprheum0905 Is rituximab suitable for use as a first-line biologic therapy for RA?

Nature Clinical Practice Rheumatology 4, 574 (2008). doi:10.1038/ncprheum0905

Authors: Anatole Kleiner & R John Looney

]]> Is rituximab suitable for use as a first-line biologic therapy for RA? Anatole Kleiner R John Looney doi:10.1038/ncprheum0905 Nature Clinical Practice Rheumatology 4, 574 (2008) 2008-09-09 Nature Clinical Practice Rheumatology 2008-09-09 4 11 Clinical Advance 574 575 Primary prevention of systemic lupus erythematosus http://dx.doi.org/10.1038/ncprheum0899 In this Viewpoint, Drs Doria and Briani highlight recent advances in efforts to improve the long-term prognosis of patients with systemic lupus erythematosus. The strategies discussed aim to prevent both the occurrence of the disease and its complications. Primary prevention of systemic lupus erythematosus

Nature Clinical Practice Rheumatology 4, 576 (2008). doi:10.1038/ncprheum0899

Authors: Andrea Doria & Chiara Briani

]]> Primary prevention of systemic lupus erythematosus Andrea Doria Chiara Briani doi:10.1038/ncprheum0899 Nature Clinical Practice Rheumatology 4, 576 (2008) 2008-09-09 Nature Clinical Practice Rheumatology 2008-09-09 4 11 Viewpoint 576 577 Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis http://dx.doi.org/10.1038/ncprheum0930 In light of the impressive efficacy of tumor necrosis factor blockers in the treatment of ankylosing spondylitis, particularly in patients with short disease duration, defining outcome parameters to monitor the structural damage of the disease has become more pertinent. In this Viewpoint the authors explore the relevance of osteoproliferation amongst other outcome parameters. Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis

Nature Clinical Practice Rheumatology 4, 578 (2008). doi:10.1038/ncprheum0930

Authors: Heiner Appel, Martin Rudwaleit & Joachim Sieper

]]> Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis Heiner Appel Martin Rudwaleit Joachim Sieper doi:10.1038/ncprheum0930 Nature Clinical Practice Rheumatology 4, 578 (2008) 2008-10-07 Nature Clinical Practice Rheumatology 2008-10-07 4 11 Viewpoint 578 579 Vitamin D and musculoskeletal health http://dx.doi.org/10.1038/ncprheum0921 Hypovitaminosis D, encompassing both vitamin D insufficiency and deficiency, is highly prevalent in the general population and has potentially deleterious musculoskeletal effects. In this Review, the authors focus on the pathophysiology, clinical correlates, evaluation and treatment of hypovitaminosis D. Vitamin D and musculoskeletal health

Nature Clinical Practice Rheumatology 4, 580 (2008). doi:10.1038/ncprheum0921

Authors: Anne E Wolff, Andrea N Jones & Karen E Hansen

]]> Vitamin D and musculoskeletal health Anne E Wolff Andrea N Jones Karen E Hansen doi:10.1038/ncprheum0921 Nature Clinical Practice Rheumatology 4, 580 (2008) 2008-10-14 Nature Clinical Practice Rheumatology 2008-10-14 4 11 Review 580 588 Dietary antioxidants in inflammatory arthritis: do they have any role in etiology or therapy? http://dx.doi.org/10.1038/ncprheum0920 The role of dietary antioxidants in the prevention and amelioration of symptoms in inflammatory joint disease has been of interest for many years. In this Review, the authors provide an overview of current evidence and discuss the potential prophylactic and therapeutic effects of antioxidants in arthritis. Dietary antioxidants in inflammatory arthritis: do they have any role in etiology or therapy?

Nature Clinical Practice Rheumatology 4, 590 (2008). doi:10.1038/ncprheum0920

Authors: Dorothy J Pattison & Paul G Winyard

]]> Dietary antioxidants in inflammatory arthritis: do they have any role in etiology or therapy? Dorothy J Pattison Paul G Winyard doi:10.1038/ncprheum0920 Nature Clinical Practice Rheumatology 4, 590 (2008) 2008-09-30 Nature Clinical Practice Rheumatology 2008-09-30 4 11 Review 590 596 Molecular effects of exercise in patients with inflammatory rheumatic disease http://dx.doi.org/10.1038/ncprheum0929 For many years, patients with chronic inflammatory disease of joints or muscles were advised to rest; however, exercise is now known to result in improved muscle performance, soft tissue integrity and health outcomes in these patients. In this Review, Dr Lundberg and Dr Nader discuss the systemic effects of exercise, as well as local effects in skeletal muscle and cartilage, in patients with rheumatic disease. Molecular effects of exercise in patients with inflammatory rheumatic disease

Nature Clinical Practice Rheumatology 4, 597 (2008). doi:10.1038/ncprheum0929

Authors: Ingrid E Lundberg & Gustavo A Nader

]]> Molecular effects of exercise in patients with inflammatory rheumatic disease Ingrid E Lundberg Gustavo A Nader doi:10.1038/ncprheum0929 Nature Clinical Practice Rheumatology 4, 597 (2008) 2008-10-07 Nature Clinical Practice Rheumatology 2008-10-07 4 11 Review 597 604 Therapeutic advances in rheumatology with the use of recombinant proteins http://dx.doi.org/10.1038/ncprheum0909 Rheumatic diseases are typified by aberrant cellular immune responses. The advent of antibody engineering has now led to the development of anti-inflammatory therapy to target these responses. In this Review, Rothe and colleagues highlight advances in recombinant technologies for the development of novel biologic therapies in rheumatology. Therapeutic advances in rheumatology with the use of recombinant proteins

Nature Clinical Practice Rheumatology 4, 605 (2008). doi:10.1038/ncprheum0909

Authors: Achim Rothe, Barbara E Power & Peter J Hudson

]]> Therapeutic advances in rheumatology with the use of recombinant proteins Achim Rothe Barbara E Power Peter J Hudson doi:10.1038/ncprheum0909 Nature Clinical Practice Rheumatology 4, 605 (2008) 2008-09-23 Nature Clinical Practice Rheumatology 2008-09-23 4 11 Review 605 614 A case of macrophage activation syndrome successfully treated with anakinra http://dx.doi.org/10.1038/ncprheum0919 This Case Study describes a 13-year-old girl with systemic juvenile idiopathic arthritis who developed features consistent with macrophage activation syndrome. The patient's disease remained active following treatment with high-dose steroids, immunoglobulin and ciclosporin, but was successfully controlled following the introduction of anakinra. A case of macrophage activation syndrome successfully treated with anakinra

Nature Clinical Practice Rheumatology 4, 615 (2008). doi:10.1038/ncprheum0919

Authors: Alison Kelly & Athimalaipet V Ramanan

]]> A case of macrophage activation syndrome successfully treated with anakinra Alison Kelly Athimalaipet V Ramanan doi:10.1038/ncprheum0919 Nature Clinical Practice Rheumatology 4, 615 (2008) 2008-09-30 Nature Clinical Practice Rheumatology 2008-09-30 4 11 Case Study 615 620